Nanfang Finance News, August 3 – Aim Vaccine (06660.HK) issued a voluntary announcement stating that its wholly-owned subsidiary, Aim Honor (Ningbo) Biopharmaceutical Co., Ltd., has independently developed a serum-free iterative rabies vaccine .(Acceptance No.: CXSS2500044) The company has completed the submission of supplementary materials required by the Center for Drug Evaluation of the National Medical Products Administration, marking significant progress in the registration application process. The vaccine has previously passed the marketing registration application and on-site inspection, and has completed the unblinding of the Phase III clinical trial. The results show that its safety, immunogenicity, and duration of immunity all fully meet the preset evaluation standards; the company has obtained the corresponding product production license. In terms of background, current mainstream rabies vaccines use a serum-containing culture system, and residual animal serum can easily cause allergies and local adverse reactions. This vaccine, however, achieves an innovative cell culture process without the addition of animal serum throughout the entire process, significantly improving safety. China is the world's largest rabies vaccine market, projected to reach RMB 14.8 billion by 2030. Furthermore, the "Guidelines for Rabies Exposure Prevention and Treatment (2023 Edition)" clearly requires vaccination clinics to be equipped with at least two different types of vaccines. This product, with its technological advantages, is expected to become the preferred choice. As the world's second-largest rabies vaccine supplier, the company has built a serum-free iterative rabies vaccine workshop that meets international standards and completed commercial-scale verification production, possessing large-scale production capabilities. Once the vaccine is approved for market launch, it is expected to significantly boost the company's performance and further solidify the company's global leading position in the field of rabies vaccines.
https://finance.eastmoney.com/a/202608033829233358.html